Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study is a research paper published in European Respiratory Journal (2020). On theSindex it has a DataRank of 3.0. It has been cited 89 times, with 69 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.675
From this paper's citation signal
Citation Network Contribution
2.3
From 53 citing papers with measurable signal
Fonds Wetenschappelijk Onderzoek
Grant: 1.8.325.12N
MeSH Terms
Additional file 10 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 10 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 11 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 11 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 12 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 12 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 13 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 13 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 14 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 14 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 1 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 1 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 2 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 2 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 3 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 3 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 4 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 4 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 5 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Additional file 5 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases